Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved

Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product. 

Mydecine focuses on developing first and second-generation novel therapeutics for the treatment of mental health disorders, mostly though not exclusively PTSD, depression, anxiety and addiction. The company seeks to collaborate with world authorities to responsibly fast-track the development of new medicines to provide with safe & effective treatment options.

The trial, conducted by Mydecine and funded by an approximate $4 million grant from the National Institutes of Health, constitutes a milestone in psychedelic studies. According to …

Full story available on Benzinga.com

More Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved